Style | Citing Format |
---|---|
MLA | Aberuyi N, et al.. "The Translational Expression of Abca2 and Abca3 Is a Strong Prognostic Biomarker for Multidrug Resistance in Pediatric Acute Lymphoblastic Leukemia." OncoTargets and Therapy, vol. 10, no. , 2017, pp. 3373-3380. |
APA | Aberuyi N, Rahgozar S, Dehaghi ZK, Moafi A, Masotti A, Paolini A (2017). The Translational Expression of Abca2 and Abca3 Is a Strong Prognostic Biomarker for Multidrug Resistance in Pediatric Acute Lymphoblastic Leukemia. OncoTargets and Therapy, 10(), 3373-3380. |
Chicago | Aberuyi N, Rahgozar S, Dehaghi ZK, Moafi A, Masotti A, Paolini A. "The Translational Expression of Abca2 and Abca3 Is a Strong Prognostic Biomarker for Multidrug Resistance in Pediatric Acute Lymphoblastic Leukemia." OncoTargets and Therapy 10, no. (2017): 3373-3380. |
Harvard | Aberuyi N et al. (2017) 'The Translational Expression of Abca2 and Abca3 Is a Strong Prognostic Biomarker for Multidrug Resistance in Pediatric Acute Lymphoblastic Leukemia', OncoTargets and Therapy, 10(), pp. 3373-3380. |
Vancouver | Aberuyi N, Rahgozar S, Dehaghi ZK, Moafi A, Masotti A, Paolini A. The Translational Expression of Abca2 and Abca3 Is a Strong Prognostic Biomarker for Multidrug Resistance in Pediatric Acute Lymphoblastic Leukemia. OncoTargets and Therapy. 2017;10():3373-3380. |
BibTex | @article{ author = {Aberuyi N and Rahgozar S and Dehaghi ZK and Moafi A and Masotti A and Paolini A}, title = {The Translational Expression of Abca2 and Abca3 Is a Strong Prognostic Biomarker for Multidrug Resistance in Pediatric Acute Lymphoblastic Leukemia}, journal = {OncoTargets and Therapy}, volume = {10}, number = {}, pages = {3373-3380}, year = {2017} } |
RIS | TY - JOUR AU - Aberuyi N AU - Rahgozar S AU - Dehaghi ZK AU - Moafi A AU - Masotti A AU - Paolini A TI - The Translational Expression of Abca2 and Abca3 Is a Strong Prognostic Biomarker for Multidrug Resistance in Pediatric Acute Lymphoblastic Leukemia JO - OncoTargets and Therapy VL - 10 IS - SP - 3373 EP - 3380 PY - 2017 ER - |